Clinical Trial Update: Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial by the National Cancer Institute evaluating vaccine therapy in combination with interleukin-2 for metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Vaccine therapy

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED